Nosopharm SAS

Lysogene Licenses Gene Therapy Candidate From Yeda Research Advancing a collaboration inked in July 2020, gene therapy specialist Lysogene SA said on 12 April that it is taking its option to license

Participants in a European Union-backed antibiotic R&D project unveiled on 1 August have talked up their chances of countering antimicrobial resistance in Gram-negative bacteria. Led by German biophar

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Genentech Looks At Oncology

Development and commercialization of a completely new class of antibiotics called Odilorhabdins is the goal behind an R&D pact between Nosopharm SAS of France and German biotech Evotec SE . Clinica